| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
3'-Hydroxymirificin targets the estrogen receptor, exhibiting estrogenic activity. As a phytoestrogenic compound, it can bind to and modulate estrogen receptor signaling pathways. The compound demonstrates activity in MCF-7 human breast carcinoma cells, which are ER-positive, indicating that its effects are mediated at least in part through estrogen receptor interactions. In addition to its estrogenic activity, 3'-Hydroxymirificin also exhibits anti-proliferative effects, suggesting potential mechanisms beyond simple estrogen receptor agonism that may involve cell cycle regulation or apoptotic pathways.
|
|---|---|
| ln Vitro |
In vitro, 3'-Hydroxymirificin possesses estrogenic activity and demonstrates anti-proliferative effects against MCF-7 human breast carcinoma cells. The compound's estrogenic activity is typically assessed using ER-positive breast cancer cell lines such as MCF-7, where it may stimulate cell proliferation at lower concentrations or inhibit proliferation at higher concentrations depending on the cellular context. The anti-proliferative effect suggests potential utility in studying natural product-based approaches to cancer treatment. The compound's activity is attributed to its isoflavonoid glycoside structure, which allows interaction with estrogen receptors and modulation of estrogen-responsive gene expression.
|
| ln Vivo |
Specific in vivo activity data for 3'-Hydroxymirificin are not extensively documented in the publicly available literature. As a naturally occurring compound isolated from Pueraria lobata roots, its in vivo effects would be expected to relate to its estrogenic and anti-proliferative properties. The compound may be investigated in animal models of hormone-related conditions such as breast cancer or osteoporosis, given its phytoestrogenic activity. However, detailed in vivo pharmacological studies have not been published. Further research is needed to characterize its bioavailability, efficacy, and safety in vivo.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 3'-Hydroxymirificin typically involve competitive binding experiments using estrogen receptors (ERα and ERβ) and radiolabeled or fluorescently labeled estradiol as tracer. The compound's ability to displace the tracer from the receptor is measured to determine binding affinity. Assays are conducted in buffered solutions at physiological pH with appropriate receptor preparations. Binding affinity is expressed as IC₅₀ or Kd values. The compound's estrogenic activity can also be assessed using reporter gene assays with estrogen response element (ERE)-luciferase constructs in transfected cells to evaluate its ability to activate ER-mediated transcription.
|
| Cell Assay |
In vitro cell-based assays for 3'-Hydroxymirificin typically utilize MCF-7 human breast carcinoma cells, an ER-positive cell line, to assess both estrogenic and anti-proliferative activities. Cells are treated with varying concentrations of the compound for 24-72 hours. Cell proliferation is measured using MTT, CCK-8, or BrdU incorporation assays. Estrogenic activity is assessed by measuring the expression of estrogen-responsive genes using qPCR or by using reporter gene assays with ERE-luciferase constructs. Standard cell culture conditions (37°C, 5% CO₂) with appropriate media and serum supplementation are employed. Dose-response curves are generated to determine EC₅₀ and IC₅₀ values.
|
| Animal Protocol |
In vivo animal studies with 3'-Hydroxymirificin would typically involve administration of the compound to rodent models to evaluate its estrogenic and anti-proliferative effects. Potential study designs include xenograft models using MCF-7 cells to assess antitumor activity, or models of hormone-related conditions such as osteoporosis to evaluate estrogenic effects. Typical endpoints would include tumor growth measurements, assessment of estrogen-responsive gene expression in target tissues, and evaluation of bone density or other relevant biomarkers. All procedures must comply with institutional animal care and use guidelines. Detailed published in vivo protocols are not currently available.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for 3'-Hydroxymirificin are not extensively documented in the publicly available literature. As a naturally occurring glycoside with a molecular weight of 564.49 g/mol, its oral bioavailability would be influenced by factors such as intestinal absorption, deglycosylation by gut microbiota, and first-pass metabolism. The compound is intended for research use only. Information concerning product stability, particularly in solution, has rarely been reported. Standard laboratory practices should be followed for storage and handling. Further studies are needed to characterize its pharmacokinetic profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3'-Hydroxymirificin are not extensively documented in the publicly available literature. As a naturally occurring compound isolated from Pueraria lobata roots, it is generally considered to have low toxicity based on the traditional use of kudzu as a food and medicinal plant. However, comprehensive toxicological studies including acute toxicity, genotoxicity, and organ-specific toxicity have not been published. The compound is intended for research use only and is not approved for human therapeutic applications. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment.
|
| References | |
| Additional Infomation |
3'-Hydroxymirificin (CAS#: 168035-02-7) has a molecular formula of C₂₆H₂₈O₁₄ and a molecular weight of 564.49 g/mol. Its IUPAC name is 8-((2S,3R,4R,5S,6R)-6-((((2R,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)-3-(3,4-dihydroxyphenyl)-7-hydroxy-4H-chromen-4-one. The compound is a natural product isolated from Pueraria lobata roots. It possesses estrogenic activity and anti-proliferation effects on MCF-7 human breast carcinoma cells. This compound is not a drug and has not undergone clinical trials for therapeutic use.
|
| Molecular Formula |
C26H28O14
|
|---|---|
| Exact Mass |
564.147
|
| CAS # |
168035-02-7
|
| PubChem CID |
145874175
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-2.1
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
40
|
| Complexity |
946
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C1[C@@]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)C3=C(C=CC4=C3OC=C(C4=O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)(CO)O
|
| InChi Key |
UXSOWCXXXQKAGC-QOIVFALESA-N
|
| InChi Code |
InChI=1S/C26H28O14/c27-8-26(36)9-39-25(24(26)35)38-7-16-19(32)20(33)21(34)23(40-16)17-14(29)4-2-11-18(31)12(6-37-22(11)17)10-1-3-13(28)15(30)5-10/h1-6,16,19-21,23-25,27-30,32-36H,7-9H2/t16-,19-,20+,21-,23+,24+,25-,26-/m1/s1
|
| Chemical Name |
8-[(2S,3R,4R,5S,6R)-6-[[(2R,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]-3-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
